These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
259 related items for PubMed ID: 26058730
1. Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®) ) in previously treated patients with severe haemophilia A: interim results of the guardian(™) 2 extension trial. Ozelo M, Misgav M, Abdul Karim F, Lentz SR, Martin-Salces M, Matytsina I, Saugstrup T, Santagostino E. Haemophilia; 2015 Sep; 21(5):e436-9. PubMed ID: 26058730 [No Abstract] [Full Text] [Related]
3. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial. Lentz SR, Janic D, Kavakli K, Miljic P, Oldenburg J, C Ozelo M, Santagostino E, Suzuki T, Zupancic Šalek S, Korsholm L, Matytsina I, Tiede A. Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994 [Abstract] [Full Text] [Related]
4. Impact of severe haemophilia A on patients' health status: results from the guardian(™) 1 clinical trial of turoctocog alfa (NovoEight(®) ). Ozelo M, Chowdary P, Regnault A, Busk AK. Haemophilia; 2015 Jul; 21(4):451-7. PubMed ID: 25677761 [Abstract] [Full Text] [Related]
9. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients. Klukowska A, Windyga J, Batorova A. Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152 [Abstract] [Full Text] [Related]
11. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial. Yaish H, Matsushita T, Belhani M, Jiménez-Yuste V, Kavakli K, Korsholm L, Matytsina I, Philipp C, Reichwald K, Wu R. Haemophilia; 2020 Jan; 26(1):64-72. PubMed ID: 31816159 [Abstract] [Full Text] [Related]
13. Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study. Khair K, Mazzucconi MG, Parra R, Santagostino E, Tsakiris DA, Hermans C, Oldenburg J, Spotts G, Steinitz-Trost K, Gringeri A. Haemophilia; 2018 Jan; 24(1):85-96. PubMed ID: 29044825 [Abstract] [Full Text] [Related]
15. Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study. Kim SK, Yoo KY, Lee KS, Hwang T, Choi YM, Choi EJ, Park SK. J Korean Med Sci; 2018 Jan 01; 33(1):e5. PubMed ID: 29215814 [Abstract] [Full Text] [Related]
19. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A. Hampton K, Chowdary P, Dunkley S, Ehrenforth S, Jacobsen L, Neff A, Santagostino E, Sathar J, Takedani H, Takemoto CM, Négrier C. Haemophilia; 2017 Sep 01; 23(5):689-696. PubMed ID: 28470862 [Abstract] [Full Text] [Related]